NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study monitors Darolutamide's safety in korean prostate cancer patients
Disease control Recruiting nowThis observational study follows 600 Korean men with prostate cancer who are already prescribed darolutamide. The goal is to track side effects and see how well the drug works over one year. Researchers will review medical records during routine doctor visits every 2 to 4 months.
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for indian men with Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is for Indian men with a type of prostate cancer that has not spread but keeps growing even when testosterone levels are very low. Participants will take darolutamide pills twice a day along with standard hormone therapy. The main goal is to check how safe the drug is …
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
Massive prostate cancer registry aims to map Real-World treatment patterns
Knowledge-focused Recruiting nowThis study is a long-term registry that will follow 5000 men with prostate cancer that has come back or spread. It includes four groups: men with a rising PSA after initial treatment, those whose cancer resists hormone therapy but hasn't spread, those with newly spread cancer, an…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 17, 2026 02:17 UTC